BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ng D, Hong CS, Singh LN, Johnston JJ, Mullikin JC, Biesecker LG. Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening. Genet Med 2017;19:357-61. [PMID: 27537706 DOI: 10.1038/gim.2016.105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Lopes JL, Harris K, Karow MB, Peterson SE, Kluge ML, Kotzer KE, Lopes GS, Larson NB, Bielinski SJ, Scherer SE, Wang L, Weinshilboum RM, Black JL 3rd, Moyer AM. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing? J Mol Diagn 2022;24:253-61. [PMID: 35041929 DOI: 10.1016/j.jmoldx.2021.11.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Lanillos J, Carcajona M, Maietta P, Alvarez S, Rodriguez-Antona C. Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data. NPJ Genom Med 2022;7:12. [PMID: 35181665 DOI: 10.1038/s41525-022-00283-3] [Reference Citation Analysis]
3 Zhang J, Qi G, Han C, Zhou Y, Yang Y, Wang X, Liu S, Zhang X. The Landscape of Clinical Implementation of Pharmacogenetic Testing in Central China: A Single-Center Study. Pharmgenomics Pers Med 2021;14:1619-28. [PMID: 34934339 DOI: 10.2147/PGPM.S338198] [Reference Citation Analysis]
4 van der Lee M, Kriek M, Guchelaar HJ, Swen JJ. Technologies for Pharmacogenomics: A Review. Genes (Basel) 2020;11:E1456. [PMID: 33291630 DOI: 10.3390/genes11121456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
5 Hlaváč V, Holý P, Souček P. Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450. J Pers Med 2020;10:E108. [PMID: 32872162 DOI: 10.3390/jpm10030108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hart MR, Garrison LP Jr, Doyle DL, Jarvik GP, Watkins J, Devine B. Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention. Value Health 2019;22:1231-9. [PMID: 31708059 DOI: 10.1016/j.jval.2019.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Jin Y, Chen G, Xiao W, Hong H, Xu J, Guo Y, Xiao W, Shi T, Shi L, Tong W, Ning B. Sequencing XMET genes to promote genotype-guided risk assessment and precision medicine. Sci China Life Sci 2019;62:895-904. [PMID: 31114935 DOI: 10.1007/s11427-018-9479-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Qiao W, Martis S, Mendiratta G, Shi L, Botton MR, Yang Y, Gaedigk A, Vijzelaar R, Edelmann L, Kornreich R, Desnick RJ, Scott SA. Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection. Pharmacogenomics 2019;20:9-20. [PMID: 30730286 DOI: 10.2217/pgs-2018-0135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Moyer AM, Caraballo PJ. The challenges of implementing pharmacogenomic testing in the clinic. Expert Rev Pharmacoecon Outcomes Res 2017;17:567-77. [PMID: 28949250 DOI: 10.1080/14737167.2017.1385395] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
10 Rajman I, Knapp L, Morgan T, Masimirembwa C. African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. EBioMedicine 2017;17:67-74. [PMID: 28237373 DOI: 10.1016/j.ebiom.2017.02.017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 8.6] [Reference Citation Analysis]